Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.50 |
| ▸ | RARB | P10826 | 3/20 | 0.47 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495309 | 1.00 | S1PR1 (0.51) | S1PR1S1PR2S1PR3S1PR4S1PR5 | |
| SCHEMBL7708500 | 0.79 | MEN1 (0.43) | S1PR1S1PR3S1PR4S1PR5RARB | |
| SCHEMBL5492443 | 0.77 | S1PR4 (0.41) | S1PR1S1PR3S1PR4S1PR5RARB | |
| SCHEMBL5492439 | 0.77 | S1PR4 (0.41) | S1PR1S1PR3S1PR4S1PR5RARB | |
| SCHEMBL7621314 | 0.76 | MEN1 (0.55) | S1PR1S1PR2S1PR3S1PR4S1PR5 | |
| SCHEMBL22384092 | 0.76 | RARB (0.49) | S1PR1S1PR3S1PR4S1PR5RARB | |
| Hydrochloric Acid SCHEMBL7624428 | 0.75 | MEN1 (0.53) | S1PR1S1PR2S1PR3S1PR4S1PR5 | |
| SCHEMBL8336704 | 0.75 | ALOX5 (0.44) | S1PR1S1PR2 | |
| SCHEMBL10825310 | 0.75 | S1PR2 (0.44) | S1PR1S1PR2S1PR3S1PR4 | |
| SCHEMBL8716239 | 0.74 | RARB (0.52) | S1PR1S1PR3S1PR4S1PR5RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | S1PR1 417/4885S1PR2 611/4885S1PR3 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.